CBA: Banking Behemoth - Party's Over, Hangover Begins
Australia's dominant bank faces cyclical normalisation from peak metrics. Fair value $122.47 vs current $185.00. Quality franchise, challenging outlook.
View noteAustralia's dominant bank faces cyclical normalisation from peak metrics. Fair value $122.47 vs current $185.00. Quality franchise, challenging outlook.
View noteSpecialised wealth management software provider trading at $2.21 vs $1.53 fair value. Strong business quality (7.6/10) with 19.5% EBITDA margins but facing competitive pressure and CEO succession uncertainty.
View noteBlueScope Steel analysis: Fair value $28.30 vs current $24.24 (16.7% upside). EBITDA margins recovering from 8.9% trough to 11.7% target. Multi-domestic strategy, net cash balance sheet.
View noteTrading at 30.0x EV/EBITDA (88% premium to peers), fair value $14.50 vs current $36.18 implies 60% downside despite strong operational metrics.
View noteGrowth equity opportunity with $4.83 fair value, 22.9% revenue CAGR, wide competitive moat, high execution risk, suitable for healthcare specialists
View noteFair value $41.52 vs current $33.29 (24.7% upside). Strong Lloyd's market access, digital platform leadership, 78% recurring revenue, defensive characteristics.
View noteAtturra trades at $0.80 vs $1.40 fair value (75% upside) with 300+ security clearances creating sovereign IT moat despite integration execution risks
View noteHOLD rating with $4.37 fair value vs $4.50 current price. Strong $14.2bn order book but execution risks during steel programme transition. 11.8% revenue CAGR forecast.
View noteAuckland Airport trades at NZ$4.36 versus fair value NZ$5.10, with 18% ROIC and 69.8% EBITDA margins offset by NZ$3.5bn Terminal Integration execution risk through FY29.
View noteInfrastructure utility trading at $8.57 vs $11.09 fair value (29.4% upside). 48% market share, 74.2% EBITDA margins, 86% contracted revenues through 2051. Energy transition risks vs defensive moat characteristics.
View noteAmotiv trades at $8.74 vs $10.21 fair value, offering 16.8% upside through defensive aftermarket positioning and $10m transformation catalyst with 22.7% EBITDA margins.
View noteAnsell trades at $31.83 vs fair value $25.40 (-20% overvalued). Strong healthcare franchise faces examination glove commoditisation pressure with 55% thesis failure probability.
View note